From 38 Finalists, RESI Boston’s Audience Selects Innovation Challenge Champions

12 Sep

By Lucy Parkinson, VP of Investor Research, LSN

Yesterday’s RESI event brought together over 350 investors and over 350 startups in Boston’s Back Bay.  There were so many meetings that RESI Partnering filled to capacity.  LSN is delighted to have facilitated so many new connections, and we hope that these relationships continue to grow in the follow-up.

The RESI Innovation Challenge showcased 38 emerging startups in the biotech, medtech, diagnostics and digital health fields.  All the competitors brought novel, exciting discoveries to the technology showcase, selected by LSN’s Expert System and scientific review team.  RESI’s attendees chose the winners by using their RESI Cash tokens to cast votes for their favorite participants.  We would like to introduce you all to the 3 top placed companies, as selected by the RESI ecosystem.  Thank you, all, for taking part by casting your votes.

First Place: Zepto Life Technologies

Zepto, an in-vitro diagnostics company, features uniquely-accurate and multiplex-ready “lab-on-a-chip” technology – co-developed with the Mayo Clinic – to improve patient outcomes through superior assay performance at patients’ exact points of need (a $12B market). Zepto’s fully-automated lab-on-a-chip Immunoassay Platform can conveniently deliver “central lab-quality” performance almost anywhere. Initially, Zepto is working to equip ERs and ambulances with highly-sensitive Troponin assays, accelerating myocardial injury detection. Meanwhile, Zepto’s portable Liquid Biopsy Platform can detect 1% cancer gene mutation (eg. PIK3CA, EGFR, KRAS) and achieve unparalleled specificity of 99.9%+ in less than 2 hours. This can revolutionize the $6B tissue-based biopsy market. Zepto seeks $30M, primarily to launch the Immunoassay Platform with D-Dimer assays and complete PIK3CA-focused product development on the Liquid Biopsy Platform.

YongYong Zhang, CEO & Co-Founder, Zepto Life Technologies


Second Place: BOYDSense

BOYDSense, Inc. is a medical technology company providing non-invasive and affordable tools for measuring critical biomarkers via exhaled breath. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. BOYDSense’s first commercial product, the g-Sense Breath Meter, is a hand-held breath meter that can accurately predict blood glucose values from breath VOC’s. The g-Sense meter does not need consumables, is wirelessly enabled, has a companion mobile application and a public API. The device design is lifestyle-friendly, pocket-sized, with a seamless user experience, allowing consumers to frequently measure blood glucose without the typical barriers of cost, pain, or social stigma.

Bruno Thuillier, CEO, BOYDSense


Third Place: Resmetrix Medical

Respiratory diseases are leading causes of death and disability in the world. More than 250 million people suffer from Chronic Obstructive Pulmonary disease (COPD) and 300 million from Asthma worldwide. Currently, respiratory deterioration is often detected too late, leading to sever exacerbation and complications, hospitalization and huge costs. Resmetrix is developing a wearable system (based on unique proprietary sensor built into a chest strap wirelessly connected to a smartphone app), that monitors at-risk respiratory patients in real-time, 24/7, anywhere, in any setting. Resmetrix system is the only system that detects small changes in a patient’s breathing pattern and provides immediate, early warning signs of deterioration in COPD patients at home, enable early window of intervention, early treatment and avoiding hospitalization.

Carmit Levy, Ph.D., CEO, Resmetrix Medical

RESI ASIA Innovation Challenge Deadline is Oct. 11th, 2019

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: